References
- Finn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/CVP in first line treatment of indolent NHL or MCL: the Bright study. Blood 2014;123:2944–2952.
- Misumi I, Whitmire JK. B cell depression crutalis CD4 + T cell memory and reduces protection against disseminating virus infection. J Immunol 2014;192;1597–1608.
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
- Layman RM, Ruppert AS, Lynn M, et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemotherapy Pharmacol 2013;71:1183–1190.
- Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine pus rituximab in patients with relapse or refractory diffuse large B cell lymphoma. J Clin Oncol 2013;31:2103–2010.
- Besada E, Koldingsnes W, Nossent C. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangitis: results from a single center. Rheumatology 2013;52:2041–2047.
- Melet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum 2013;65:2783–2790.
- Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin's lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21–27.
- Lim SH, Pathapati S, Langevin J, et al. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 2012;91:643.
- Carter SJ, Bernstein SH, Friedberg JW, et al. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res 2011;35:e233–e234.